Clinical Trial

Treatment to Regress to Normoglycemia in Women with a Recent History of GDM

Study acronym: SWEET
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 13, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the study is to determine the efficacy of semaglutide 1mg (Ozempic®) to aid recently postpartum women with dysglycemia and a history of GDM to regress to normoglycemia; thereby filling a gap in efficacious pharmacologic intervention options for clinicians to support postpartum diabetes recovery and reduce future risk of T2DM in young women.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-04-29; most recent amendment 2025-03-10.
Status change: Not Yet Recruiting → Recruiting 2022-01-25
Trial Details
NCT Number NCT04873050
Lead Sponsor Woman's
Collaborators: Novo Nordisk A/S
Conditions Pre Diabetes, Postpartum Disorder
Enrollment 102 participants
Start Date 2022-01-13
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-13